Clinical, Biological, and Skin Histopathologic Effects of Ionic Macrocyclic and Nonionic Linear Gadolinium Chelates in a Rat Model of Nephrogenic Systemic Fibrosis

Objective:The purpose of this study was to compare the clinical, pathologic, and biochemical effects of repeated administrations of ionic macrocyclic or nonionic linear gadolinium chelates (GC) in rats with impaired renal function. Material and Methods:Rats submitted to subtotal nephrectomy were allocated to single injections of 2.5 mmol/kg of gadodiamide (nonionic linear chelate), nonformulated gadodiamide (ie, without the free ligand caldiamide), gadoterate (ionic macrocyclic chelate), or saline for 5 consecutive days. Blinded semi-quantitative histopathologic and immunohistochemical examinations of the skin were performed, as well as clinical, hematological, and biochemical follow-up. Rats were killed at day 11. Long-term (up to day 32) follow-up of rats was also performed in an auxiliary study. Results:Epidermal lesions (ulcerations and scabs) were found in 4 of the 10 rats treated with nonformulated gadodiamide. Two rats survived the study period. Inflammatory signs were observed in this group. No clinical, hematological, or biochemical signs were observed in the saline and gadoterate- or gadodiamide-treated groups. Plasma fibroblast growth factor-23 levels were significantly higher in the gadodiamide group than in the gadoterate group (day 11). Decreased plasma transferrin-bound iron levels were measured in the nonformulated gadodiamide group. Histologic lesions were in the range: nonformulated gadodiamide (superficial epidermal lesions, inflammation, necrosis, and increased cellularity in papillary dermis) > gadodiamide (small superficial epidermal lesions and signs of degradation of collagen fibers in the dermis) > gadoterate (very few pathologic lesions, similar to control rats). Conclusions:Repeated administration of the nonionic linear GC gadodiamide to renally impaired rats is associated with more severe histologic lesions and higher FGF-23 plasma levels than the macrocyclic GC gadoterate.

[1]  T. Steger-Hartmann,et al.  A Review of Preclinical Safety Data for Magnevist (Gadopentetate Dimeglumine) in the Context of Nephrogenic Systemic Fibrosis , 2010, Investigative radiology.

[2]  S. Morcos,et al.  Nephrogenic Gadolinium Biodistribution and Skin Cellularity Following a Single Injection of Omniscan in the Rat , 2010, Investigative radiology.

[3]  R. Swartz,et al.  Collagenolytic Activity Is Suppressed in Organ-Cultured Human Skin Exposed to a Gadolinium-Based MRI Contrast Agent , 2010, Investigative radiology.

[4]  W. Weidenmaier,et al.  NSF after Gadovist exposure: a case report and hypothesis of NSF development. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  T. Leiner,et al.  Special issue: Nephrogenic systemic fibrosis , 2009, Journal of magnetic resonance imaging : JMRI.

[6]  J. Weinreb,et al.  Gadolinium‐based contrast agents and nephrogenic systemic fibrosis: Why did it happen and what have we learned? , 2009, Journal of magnetic resonance imaging : JMRI.

[7]  T. Steger-Hartmann,et al.  Gadolinium‐based contrast agents and NSF: Evidence from animal experience , 2009, Journal of magnetic resonance imaging : JMRI.

[8]  S. Jimenez,et al.  Mechanism of NSF: New evidence challenging the prevailing theory , 2009, Journal of magnetic resonance imaging : JMRI.

[9]  T. Steger-Hartmann,et al.  The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. , 2009, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

[10]  R. Herfkens,et al.  Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. , 2009, Radiology.

[11]  J. García-Erce,et al.  An update on iron physiology. , 2009, World journal of gastroenterology.

[12]  L. Chibnik,et al.  Nephrogenic systemic fibrosis after gadopentetate dimeglumine exposure: case series of 36 patients. , 2009, Radiology.

[13]  E. Lancelot,et al.  Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. , 2009, Radiologic clinics of North America.

[14]  H. Thomsen,et al.  Nephrogenic systemic fibrosis: history and epidemiology. , 2009, Radiologic clinics of North America.

[15]  R. Swartz,et al.  Regulation of Collagen Turnover in Human Skin Fibroblasts Exposed to a Gadolinium-Based Contrast Agent , 2009, Investigative radiology.

[16]  G. Wolf,et al.  TGF-beta and fibrosis in different organs - molecular pathway imprints. , 2009, Biochimica et biophysica acta.

[17]  T. Steger-Hartmann,et al.  Evaluating the role of zinc in the occurrence of fibrosis of the skin: A preclinical study , 2009, Journal of magnetic resonance imaging : JMRI.

[18]  T. Steger-Hartmann,et al.  Impact of Renal Impairment on Long-Term Retention of Gadolinium in the Rodent Skin Following the Administration of Gadolinium-Based Contrast Agents , 2009, Investigative radiology.

[19]  D. Løvhaug,et al.  Effects of gadolinium contrast agents in naïve and nephrectomized rats: Relevance to nephrogenic systemic fibrosis , 2009, Acta radiologica.

[20]  R. Herfkens,et al.  Nephrogenic Systemic Fibrosis in Patients With Chronic Kidney Disease Who Received Gadopentetate Dimeglumine , 2009, Investigative radiology.

[21]  M. Perazella,et al.  Current status of gadolinium toxicity in patients with kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[22]  G. Schett,et al.  Monocyte Chemoattractant Proteins in the Pathogenesis of Systemic Sclerosis , 2008 .

[23]  Diego R Martin,et al.  Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. , 2008, Radiology.

[24]  E. Lancelot,et al.  Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. , 2008, Toxicology.

[25]  T. Frenzel,et al.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions , 2008, European Radiology.

[26]  D. Broome,et al.  Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. , 2008, European journal of radiology.

[27]  P. Stratta,et al.  Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy. , 2008, Current medicinal chemistry.

[28]  C. Robic,et al.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review , 2008, BioMetals.

[29]  M. Perazella.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Tissue Deposition of Gadolinium and Development of NSF: A Convergence of Factors , 2008, Seminars in dialysis.

[30]  R. Reilly,et al.  NSF: WHAT WE KNOW AND WHAT WE NEED TO KNOW: Nephrogenic Systemic Fibrosis Risk: Is There a Difference between Gadolinium‐Based Contrast Agents? , 2008 .

[31]  T. Frenzel,et al.  A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media , 2008, Investigative radiology.

[32]  Frank J Rybicki,et al.  Biochemical safety profiles of gadolinium‐based extracellular contrast agents and nephrogenic systemic fibrosis , 2007, Journal of magnetic resonance imaging : JMRI.

[33]  L. Quarles,et al.  How fibroblast growth factor 23 works. , 2007, Journal of the American Society of Nephrology : JASN.

[34]  S. Morcos,et al.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? , 2007, The British journal of radiology.

[35]  R. Bucala.  Fibrocytes: Discovery of a Circulating Connective Tissue Cell Progenitor , 2007 .

[36]  S. Cowper.  Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. , 2007, Advances in dermatology.

[37]  M. Port,et al.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review , 2006, Fundamental & clinical pharmacology.

[38]  F Verrecchia,et al.  [Cellular and molecular mechanisms of fibrosis]. , 2006, Annales de pathologie.

[39]  A. Ooshima,et al.  Up-regulation of Cbfa1 and Pit-1 in calcified artery of uraemic rats with severe hyperphosphataemia and secondary hyperparathyroidism. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[40]  S. Cowper,et al.  Nephrogenic systemic fibrosis: An update , 2006, Current rheumatology reports.

[41]  Oprs Alert.  Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers , 2005 .

[42]  S. Jimenez,et al.  Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. , 2004, Arthritis and rheumatism.

[43]  Dawn G Goodman,et al.  Best Practices Guideline: Toxicologic Histopathology , 2004, Toxicologic pathology.

[44]  T. Singer,et al.  Comparison of clinical pathology parameters with two different blood sampling techniques in rats: retrobulbar plexus versus sublingual vein , 2000, Laboratory animals.

[45]  Sato,et al.  Augmented production of chemokines (monocyte chemotactic protein‐1 (MCP‐1), macrophage inflammatory protein‐1α (MIP‐1α) and MIP‐1β) in patients with systemic sclerosis: MCP‐1 and MIP‐1α may be involved in the development of pulmonary fibrosis , 1999 .

[46]  M. Hasegawa,et al.  Augmented production of chemokines (monocyte chemotactic protein-1 (MCP-1), macrophage inflammatory protein-1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. , 1999, Clinical and experimental immunology.

[47]  B. Rovin,et al.  Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[48]  E. Holtz,et al.  Preclinical safety assessment and pharmacokinetics of gadodiamide injection, a new magnetic resonance imaging contrast agent. , 1993, Investigative radiology.

[49]  A. Martell,et al.  New synthetic, selective, high-affinity ligands for effective trivalent metal ion binding and transport , 1992 .

[50]  H. Niendorf,et al.  Tolerance data of Gd-DTPA: a review. , 1991, European journal of radiology.

[51]  J. Wittenberg,et al.  Gd-DOTA: characterization of a new paramagnetic complex. , 1988, Radiology.

[52]  A. Prasad.  Clinical manifestations of zinc deficiency. , 1985, Annual review of nutrition.